View source for Nicholas J. Vogelzang

{{SI}}


==Overview==
Dr '''Nicholas J. Vogelzang''' was appointed as the Director of the [[Nevada Cancer Institute]] (NVCI) in January of 2004. His research interests are in [[clinical trials]] in genitourinary malignancies and [[mesothelioma]]. He is also involved in new therapies for patients with metastatic [[kidney cancer]], including [[gene therapy]] and cytokine therapy. 

== Career ==
Dr. Vogelzang received his [[M.D.]] degree from the [[University of Illinois at Chicago]] in 1974. He completed his internship, residency, and chief residency in internal medicine at [[Rush-Presbyterian-St. Luke's Medical Center]] in [[Chicago]], followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. 

He served as a faculty member at the [[University of Chicago]] since 1982 including serving as the director of the University of Chicago Cancer Research Center.

== Research == 
In 2002, Vogelzang directed the largest Phase II trial for [[mesothelioma]] using [[pemetrexed]] (brand name Alimta&reg;, by [[Eli Lilly and Company|Eli Lilly]]).  Pemetrexed is an antifolate, a class of drugs that targets the folic acid metabolic pathway. The results of the trial show that tumors shrank in 41 percent of patients on pemetrexed in combination with a more commonly used [[chemotherapy]] agent called [[cisplatin]]. Only 17 percent of patients receiving cisplatin alone experienced tumor shrinkage. Additionally, those on the pemetrexed combination lived nearly three months longer than those on cisplatin alone. [http://www.mesotheliomaweb.org/pemetrexed.htm] [http://www.ALIMTA.com]

== Professional memberships == 
Dr. Vogelzang has served on committees of the [[American Society of Clinical Oncology]] (ASCO), as well as on its Board of Directors from 1993 to 1996. He is a former president of the Illinois Division of the American Cancer Society. Dr. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, Chair of the CALGB Prostate Committee from 1993 to 1999.

He is a founding board member of the [[Mesothelioma Applied Research Foundation]] (MARF) and is a member the American Association for Cancer Research, the American Urological Association, the Society of Urologic Oncology and the European Society for Medical Oncology.

== Corporate relationships ==
Vogelzang is a member of the scientific advisory board for Advanced Life Sciences which is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, inflammation and oncology.

[[Category:Oncologists|Vogelzang, Nicholas J.]]
[[Category:American physicians|Vogelzang, Nicholas J.]]

{{WH}}
{{WikiDoc Sources}}